| Oral lupus erythematosus: Immunohistochemical evaluation of CD1a, CD21, CD123, and langerin expression in dendritic cells. | Oral lupus erythematosus: Immunohistochemical evaluation of CD1a, CD21, CD123, and langerin expression in dendritic cells.
Marques ERMDC, Hsieh R, Lourenço SV, Nico MMS. | 04/15/2024 |
| Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia. | Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY, Bian MR, Lin GQ, Yu L, Zhang YM, Wu DP. | 12/27/2023 |
| High placental expression of FLT1, LEP, PHYHIP and IL3RA - In persons of African ancestry with severe preeclampsia. | High placental expression of FLT1, LEP, PHYHIP and IL3RA - In persons of African ancestry with severe preeclampsia.
Aisagbonhi O, Bui T, Nasamran CA, St Louis H, Pizzo D, Meads M, Mulholland M, Magallanes C, Lamale-Smith L, Laurent LC, Morey R, Jacobs MB, Fisch KM, Horii M., Free PMC Article | 12/20/2023 |
| Conformational and binding mode assessment of the human IL-3 recognition by its alpha receptor. | Conformational and binding mode assessment of the human IL-3 recognition by its alpha receptor.
Fogha J, de Brevern AG, Diharce J. | 06/12/2023 |
| CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. | CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
Pelosi E, Castelli G, Testa U., Free PMC Article | 02/16/2023 |
| Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-beta and tau pathology in Alzheimer's disease. | Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
Wang ZB, Ma YH, Sun Y, Tan L, Wang HF, Yu JT, Alzheimer’s Disease Neuroimaging Initiative., Free PMC Article | 01/11/2023 |
| Expression of CD123 Related Long Non-coding RNA in Acute Myeloid Leukemia Bone Marrow Mononuclear Cells and Its Clinical Significance. | Expression of CD123 Related Long Non-coding RNA in Acute Myeloid Leukemia Bone Marrow Mononuclear Cells and Its Clinical Significance.
Feng Y, Su B, Xu Y, He Y, He R, Ge F. | 10/22/2022 |
| The Expressions of CD30 and CD123 of Mastocytosis in Taiwan. | The Expressions of CD30 and CD123 of Mastocytosis in Taiwan.
Yang CF, Hsu CY. | 04/23/2022 |
| CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. | CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Lamble AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, Pardo L, Sung L, Cooper TM, Kolb EA, Aplenc R, Tasian SK, Loken MR, Meshinchi S., Free PMC Article | 02/26/2022 |
| Two New Neutrophil Subsets Define a Discriminating Sepsis Signature. | Two New Neutrophil Subsets Define a Discriminating Sepsis Signature.
Meghraoui-Kheddar A, Chousterman BG, Guillou N, Barone SM, Granjeaud S, Vallet H, Corneau A, Guessous K, de Roquetaillade C, Boissonnas A, Irish JM, Combadière C. | 01/29/2022 |
| CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. | CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma.
Lyapichev KA, Sukswai N, Angelova E, Kersh MJ, Pierce S, Konopleva M, Jain N, Jabbour EJ, Jorgensen JL, Wang SA, Medeiros LJ, Khoury JD, Konoplev S. | 01/15/2022 |
| Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations. | Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
Soare DS, Radu E, Dumitru I, Vlădăreanu AM, Bumbea H. | 11/6/2021 |
| Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A., Free PMC Article | 09/18/2021 |
| The RNFT2/IL-3Ralpha axis regulates IL-3 signaling and innate immunity. | The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity.
Tong Y, Lear TB, Evankovich J, Chen Y, Londino JD, Myerburg MM, Zhang Y, Popescu ID, McDyer JF, McVerry BJ, Lockwood KC, Jurczak MJ, Liu Y, Chen BB., Free PMC Article | 06/26/2021 |
| Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients. | Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
Aref S, Azmy E, El Ghannam D, Haroun M, Ibrahim L, Sabry M. | 06/12/2021 |
| Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia. | Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
Kandeel EZ, Madney Y, Eldin DN, Shafik NF. | 05/1/2021 |
| FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression. | FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
Soare DS, Radu E, Dumitru I, Popov VM, Bumbea H, Vlădăreanu AM., Free PMC Article | 05/1/2021 |
| CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. | CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F. | 01/9/2021 |
| CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia. | CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia.
Shi M, Su RJ, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M. | 08/13/2020 |
| Prognostic relevance of CD123 expression in adult AML with normal karyotype. | Prognostic relevance of CD123 expression in adult AML with normal karyotype.
Jiang G, Atenafu EG, Capo-Chichi JM, Minden MD, Chang H. | 07/11/2020 |
| Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker. | Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker.
Fraga GR, Chow P. | 06/6/2020 |
| Coexpression of TCF4 and CD123 is a highly reliable feature of blastic plasmacytoid dendritic cell neoplasms. | Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. | 04/11/2020 |
| expression of CD44, CD87 and CD123 in different phenotype of acute leukemia are different, which correlateds with prognosis | [Expression of CD44, CD87 and CD123 in Acute Leukemia and Its Correlation with Cellular Immunity].
Wang SW, Yao HX, Rao R, Xia MJ. | 12/28/2019 |
| CD123 expression may thus be useful for assessing AML patients' prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients. | Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
Arai N, Homma M, Abe M, Baba Y, Murai S, Watanuki M, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Saito B, Shiozawa E, Harada H, Yamochi-Onizuka T, Nakamaki T, Takimoto M. | 05/4/2019 |
| High IL3RA expression is associated with breast cancer. | IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.
Lombardo G, Gili M, Grange C, Cavallari C, Dentelli P, Togliatto G, Taverna D, Camussi G, Brizzi MF., Free PMC Article | 03/9/2019 |